ASX:CSLBiotechs
How Investors May Respond To CSL (ASX:CSL) Downplaying Impact Of New US Drug Tariffs
CSL has recently indicated that new United States tariffs on imported pharmaceuticals are expected to have minimal impact on its business, as most plasma-derived therapies are exempt and the company is continuing a US$1.50 billion expansion of its plasma manufacturing capacity in Illinois.
The company also expects tariffs on Fluad, its key US flu vaccine manufactured in the United Kingdom, to fall from 10% to zero by late 2026, highlighting how its growing US production base and evolving...